Methods and compositions involving nucleotide repeat disorders
View Patent ↗The present invention concerns the methods and compositions involving nucleic acids with long repeat sequences. In some embodiments of the invention, there are methods for generating such a nucleic acid, and in other methods, there are methods for using such a nucleic acid to screen for candidate therapeutic compounds. Furthermore the present invention relates to methods of screening for Notch inhibitors and other substances that may be used to treat muscle loss and wasting.
1. A method of screening for a candidate therapeutic agent for the treatment of myotonic dystrophy type 1 (DM1) comprising:
(a) incubating a skeletrophin polypeptide with RNA molecules containing 100 to 5000 CUG trinucleotide repeats under conditions in which the skeletrophin polypeptide associates with the RNA molecules;
(b) incubating a candidate compound with the RNA molecules, skeletrophin polypeptide, or both; and
(c) determining whether the candidate compound disrupts or inhibits the association between the skeletrophin polypeptide and the RNA molecules;
wherein a candidate compound that disrupts or inhibits the association is a candidate therapeutic agent for the treatment of DM1.
2. The method of claim 1 , wherein the RNA molecules are dystrophia myotonica protein kinase (DMPK) transcripts.
3. The method of claim 1 , wherein determining whether the candidate compound disrupts or inhibits the association between the skeletrophin polypeptide and the RNA molecules involves assaying for sequestration of the skeletrophin polypeptide, wherein a decrease in sequestration identifies the candidate compound as a candidate therapeutic agent.
4. The method of claim 3 , wherein determining whether the candidate compound disrupts or inhibits the association between the skeletrophin polypeptide and the RNA molecules involves assaying Notch activity, wherein a decrease in Notch activity identifies the candidate compound as a candidate therapeutic agent.
5. The method of claim 1 , wherein determining whether the candidate compound disrupts or inhibits the association between the skeletrophin polypeptide and the RNA molecules involves assaying for binding between the skeletrophin polypeptide and the RNA molecules, wherein a reduction or inhibition of binding identifies the candidate compound as a candidate therapeutic agent.